DEFA14A 1 d920286ddefa14a.htm DEFA14A DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Filed by the Registrant 

Filed by a Party other than the Registrant 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

Enliven Therapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table below in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 
 


 

LOGO

 

P.O. BOX 8016, CARY, NC 27512-9903

 

LOGO

   LOGO

 

 

 

Enliven Therapeutics, Inc.

 

Annual Meeting of Stockholders

 

Tuesday, June 24, 2025 1:00 p.m., Mountain Time

 

Annual meeting to be held virtually via the internet - please visit www.proxydocs.com/ELVN for more details.

 

You must register to attend the meeting online and/or participate at www.proxydocs.com/ELVN

 

 

For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/ELVN

 

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

 

This communication is not a form for voting and presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

 

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 13, 2025.

       

 

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

 

Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 24, 2025 for stockholders of record as of April 25, 2025

 

To order paper materials, use one of the following methods.

 

LOGO

 

Internet:

www.investorelections.com/ELVN

 

LOGO

 

Call:

1-866-648-8133

 

LOGO

 

Email:

paper@investorelections.com

 

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

 

         

LOGO

   
     

Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

SEE REVERSE FOR FULL AGENDA      

Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


 

LOGO    Enliven Therapeutics, Inc. Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR the election of the three Class II directors

FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for

fiscal year ending December 31, 2025

 

    

 

PROPOSAL

 

1.    To elect the three Class II directors named in the accompanying proxy statement to serve until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
   1.01 Rahul D. Ballal, Ph.D.
   1.02 Jake Bauer, M.B.A
   1.03 Andrew Phillips, Ph.D.
2.    To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025.
3.    To transact other business that may properly come before the Annual Meeting of Stockholders.

Note: In their discretion, the Named Proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. If no direction is made, this proxy will be voted “FOR” the election of each nominee in Proposal 1 and “FOR” Proposal 2.